|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||61.43 - 63.30|
|52-week range||50.21 - 74.34|
|Beta (5Y monthly)||1.12|
|PE ratio (TTM)||26.53|
|Forward dividend & yield||2.11 (3.26%)|
|Ex-dividend date||02 May 2022|
|1y target est||N/A|
(Reuters) -The U.S. Supreme Court on Monday rejected another Bayer AG bid to dismiss litigation alleging that its Roundup weedkiller causes cancer as the German pharmaceutical and chemical giant tries to avoid potentially billions of dollars in damages. The justices turned away a Bayer appeal and left in place a lower court decision upholding an $87 million judgment awarded in a lawsuit in California to Alberta and Alva Pilliod, who were diagnosed with cancer after spraying Roundup for more than three decades. The Supreme Court on June 21 rejected a Bayer appeal in a different Roundup case.
U.S. farmers have cut back on using common weedkillers, hunted for substitutes to popular fungicides and changed planting plans over persistent shortages of agricultural chemicals that threaten to trim harvests. Spraying smaller volumes of herbicides and turning to less-effective fungicides increase the risk for weeds and diseases to dent crop production at a time when global grain supplies are already tight because the Ukraine war is reducing the country's exports. Interviews with more than a dozen chemical dealers, manufacturers, farmers and weed specialists showed shortages disrupted U.S. growers' production strategies and raised their costs.
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and AstraZeneca PLC (AZN).